A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Major depressive disorder is a serious, recurrent and disabling mental disorder, which is the
second leading cause of years lost to disability worldwide. Accumulating evidence suggests
the important role for inflammation and oxidative stress in the pathophysiology of
depression. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant
and anti-inflammatory activity. Previous studies suggested sulforaphane activates Keap1-Nrf2
system to prevent depression-like phenotype in mice. In this study, the investigator attempts
to evaluate the efficacy, safety, and tolerability of sulforaphane plus a fixed oral
antipressant in adult participants diagnosed with depression.